Evidence map›Paper›PMID 20015988›Full record

ArticleJournal of virology2010

Augmented latent membrane protein 1 expression from Epstein-Barr virus episomes with minimal terminal repeats.

Allison M Repic, Mingxia Shi, Rona S Scott, John W Sixbey

Abstract read
In one paragraph

Article in Journal of virology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Allison M RepicCenter for Molecular and Tumor Virology, Louisiana State University Health Sciences Center, Shreveport, Louisiana 71130, USA.
Mingxia Shi
Rona S Scott
John W Sixbey
National Center for Tumor Diseases · DELouisiana State University Health Sciences Center Shreveport · US

Funding

RECRUITMENT YEAR FOR PI#5P20RR018724 · NCRR · LOUISIANA STATE UNIV HSC SHREVEPORT · PI O'CALLAGHAN, DENNIS JOHN · 2003 to 2011
$16.1M
Epstein-Barr Virus-Enhanced Tumor ProgressionR01CA114416 · NCI · LOUISIANA STATE UNIV HSC SHREVEPORT · PI SCOTT, RONA S · 2006 to 2010
$1.4M
NCI NIH HHS CA114416NCI NIH HHS R01 CA114416NCRR NIH HHS P20 RR018724
6 · The paper itself

Abstract

The major oncogene of the Epstein-Barr virus (EBV), latent membrane protein 1 (LMP1), can be expressed from either of two promoters, ED-L1 or L1-TR, producing mRNAs of 2.8 kb or 3.5 kb, respectively. L1-TR, active in nasopharyngeal carcinoma and Hodgkin's lymphoma, is located within the first of a highly variable reiteration of terminal repeat (TR) sequences that are joined by random recombination upon circularization of the linear genome at entry into cells. To determine whether the resultant TR number affects LMP1 promoter activity, we isolated single-cell clones bearing episomes of distinct TR numbers (6TR to 12TR) from epithelial cells newly infected with EBV. LMP1 mRNA levels correlated directly with the quantity of LMP1 protein expressed but varied inversely to TR number. Unexpectedly, the 3.5-kb transcript predominated only at lower TR reiterations. Diminished L1-TR activity in the context of a higher TR count was confirmed with a green fluorescent protein (GFP) reporter construct driven by L1-TR. Various levels of LMP1, expressed from virus isogenic in all but TR number, produced divergent morphological and growth phenotypes in each cell clone. Abundant LMP1 in 6TR cells yielded a relatively cytostatic state compared to the proliferative one produced by intermediate and smaller amounts in 8TR and 12TR clones. These findings suggest that the diversification of TR number, inherent in a round of EBV reactivation and reinfection, may itself be a component of the oncogenic process. The replicative burst preceding onset of many EBV-linked cancers may increase the likelihood that LMP1 levels compatible with clonal outgrowth are achieved in a subset of infected cells.

Indexed as

Herpesvirus 4, HumanPlasmidsPromoter Regions, GeneticViral Matrix ProteinsCell Line, TumorEpithelial CellsGene DosageGene Expression Regulation, ViralHumansPhenotypeTerminal Repeat SequencesEBV-associated membrane antigen, Epstein-Barr virusViral Matrix Proteins

Identifiers

PMID20015988
PMCPMC2820940
OpenAlexW2000684462

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.